TSHA · Taysha Gene Therapies, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200,000 |
| 2026-06-01 | Donenberg Phillip B. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
21,335 |
| 2026-06-01 | Donenberg Phillip B. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
42,671 |
| 2026-06-01 | Stalfort John A III |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
42,671 |
| 2026-06-01 | Long Alison S |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
21,335 |
| 2026-06-01 | Sepp-Lorenzino Laura |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
42,671 |
| 2026-06-01 | Long Alison S |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
42,671 |
| 2026-06-01 | Sepp-Lorenzino Laura |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
21,335 |
| 2026-06-01 | Stalfort John A III |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
21,335 |
| 2026-04-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200,000 |
| 2026-04-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
19,021 |
| 2026-04-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
19,021 |
| 2026-02-04 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. |
Common Stock
|
1,655 |
| 2026-01-26 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. |
Common Stock
|
23,849 |
| 2026-01-26 | Nolan Sean P. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. |
Common Stock
|
41,312 |
| 2026-01-26 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. |
Common Stock
|
26,918 |
| 2026-01-23 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). |
Common Stock
|
78,968 |
| 2026-01-23 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). |
Common Stock
|
89,132 |
| 2026-01-23 | Nolan Sean P. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). |
Common Stock
|
136,789 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
111,324 |
| 2026-01-12 | Nolan Sean P. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
648,000 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
274,000 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
88,676 |
| 2026-01-12 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
231,000 |
| 2026-01-12 | Nolan Sean P. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. |
Common Stock
|
1,008,000 |
| 2026-01-12 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. |
Common Stock
|
359,000 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
111,324 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200,000 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
88,676 |
| 2026-01-12 | Nagendran Sukumar |
Director, President and Head of R&D |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. |
Common Stock
|
427,000 |
| 2025-12-01 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive. |
Common Stock
|
260,047 |
| 2025-12-01 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
260,047 |
| 2025-12-01 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
260,047 |
| 2025-11-28 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
39,953 |
| 2025-11-28 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2). |
Common Stock
|
110,125 |
| 2025-11-28 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
70,172 |
| 2025-11-28 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
39,953 |
| 2025-11-28 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
70,172 |
| 2025-09-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200,000 |
| 2025-09-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |
Employee Stock Option (right to buy)
|
41,150 |
| 2025-09-10 | Nagendran Sukumar |
Director, President and Head of R&D |
Convert↑
|
Common Stock
|
41,150 |
| 2025-08-21 | Alam Kamran |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
54,491 |
| 2025-08-21 | Nagendran Sukumar |
Director, President and Head of R&D |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
57,054 |
| 2025-06-02 | Donenberg Phillip B. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
113,246 |
| 2025-06-02 | Long Alison S |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
113,246 |
| 2025-06-02 | Sepp-Lorenzino Laura |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
56,623 |
| 2025-06-02 | Sepp-Lorenzino Laura |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Stock Option (right to buy)
|
113,246 |
| 2025-06-02 | Donenberg Phillip B. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
56,623 |
| 2025-06-02 | Long Alison S |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
56,623 |
| 2025-06-02 | Stalfort John A III |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Common Stock
|
56,623 |